<DOC>
	<DOCNO>NCT02234999</DOCNO>
	<brief_summary>To evaluate metabolism excretion [ 14C ] -CC-122 healthy male subject</brief_summary>
	<brief_title>Radiolabeled Study CC-122 Healthy Subjects</brief_title>
	<detailed_description>This single-center , open-label study evaluate metabolism excretion [ 14C ] -CC-122 follow single oral dose [ 14C ] -CC-122 healthy male subject . It plan 6 subject enrol ; subject participate screening phase , baseline phase , treatment phase , follow phone call . Blood , urine fecal sample collect analysis .</detailed_description>
	<criteria>1 . Healthy adult male race 18 year age 55 year age , inclusive , time signing informed consent document . 2 . Understand voluntarily sign informed consent document study relate assessments/procedures perform . 3 . Able adhere study visit schedule protocol requirement . 4 . Must practice true abstinence agree use condom ( latex condom recommend ) sexual contact pregnant female female childbearing potential participate study least 28 day follow discontinuation investigational product , even undergone successful vasectomy . 5 . Must agree abide CC 122 Pregnancy Prevention Risk Management Plan 6 . Must body mass index 18 33 kg/m2 , inclusive , screen . 7 . Must healthy determine Investigator basis medical history , physical exam , clinical laboratory test result , vital sign , 12lead electrocardiogram screening : Must afebrile ( febrile define ≥ 38.5°C 101.3°F ) Supine systolic blood pressure must range 90 140 mmHg , supine diastolic blood pressure must range 50 90 mmHg , pulse rate must range 40 110 bpm Normal clinically acceptable 12 lead electrocardiogram , QTcF value ≤ 430 msec 1 . History clinically significant relevant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychological , pulmonary , metabolic , endocrine , hematological , allergic disease , drug allergy ( include know hypersensitivity member class IMiDs® ) , major disorder . 2 . Any condition , include presence clinically significant laboratory abnormality , place subject unacceptable risk participate study . 3 . Any condition confound ability interpret data study . 4 . Exposed investigational drug ( new chemical entity ) within 30 day precede dose administration , five half live investigational drug , know ( whichever longer ) . 5 . Participation one radiolabeled investigational drug study within 12 month prior check . Note : The previous radiolabeled investigational drug must receive 6 month prior check total planned exposure current study previous study must within recommend level consider safe , per United States Code Federal Regulations govern Protection Human Subjects ; radioactive drug certain research use . 6 . Exposure significant radiation ( example , serial Xray compute tomography scan , barium meal , current employment job require radiation exposure monitoring ) within 12 month prior check . 7 . Used prescribed systemic topical medication ( include limit analgesic , anesthetic , etc ) within 30 day dose administration . 8 . Used nonprescribed systemic topical medication ( include vitamin/mineral supplement , herbal medicine ) within 14 day dose administration . 9 . Used cytochrome P450 3A inducer and/or inhibitor ( include St. John 's wort ) within 30 day dose administration . 10 . Received live vaccination within 90 day dose administration . 11 . Has surgical medical condition possibly affect absorption , distribution , metabolism , and/or elimination , example , bariatric procedure , plan elective medical procedure perform conduct trial . Prior appendectomy acceptable , prior cholecystectomy would result exclusion study . 12 . Donated blood plasma within 8 week dose administration blood bank blood donation center . 13 . History drug abuse ( define current version Diagnostic Statistical Manual ) within 2 year dose administration , positive drug screen test reflect consumption illicit drug . 14 . History alcohol abuse ( define current version Diagnostic Statistical Manual ) within 2 year dose administration , positive alcohol screen . 15 . Known serum hepatitis know carrier hepatitis B surface antigen hepatitis C antibody , positive result test HIV antibodies screen . 16 . Smokes 10 cigarette per day , equivalent tobacco product ( self report ) . 17 . Part clinical site staff personnel family member clinical site staff . 18 . History le one two bowel movement per day .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pharmacokinetics , Healthy Subjects</keyword>
</DOC>